Table 1.
Product Name | Mode of Administration/Mechanism of Action | Recommendation |
---|---|---|
Mucus therapies | ||
Deoxyribonuclease (hrDNase) | Nebulized solution Mucolytic compound Cleaves extracellular DNA |
Not recommended [35] May be considered as a therapeutic option for atelectasis in severe cases, when conventional therapy is unsuccessful [36] |
N-acetylcysteine | Nebulized solution Poor bioavailability of oral preparation [37] Mucolytic compound Hydrolyzes disulfide bonds of mucus proteins Antioxidant properties [38] |
Insufficient data—further studies needed Not recommended |
3% hypertonic saline | Nebulized solution Creates osmotic gradient and pulls water into the mucus layer Improves ciliary activity Stimulates cough May reduce airway edema [39] |
May reduce the risk of hospitalization in the ED setting [40] Not recommended for inpatient management May modestly reduce the duration of admission for infants admitted >72 h—further studies needed [40,41] |
Bronchodilators | ||
Salbutamol, albuterol, etc. | Nebulized solution β-2 adrenergic receptor agonist, relaxes smooth muscle and opens airways |
Not recommended [33] Can be trialled to assess the response in certain cases and given where a benefit is seen |
Epinephrine | Nebulized solution Some β-2 adrenergic effects Vasoconstriction due to α-1 adrenergic receptor effects also decrease airway edema |
May reduce risk of hospitalization in the ED setting [42] Not recommended [43] |
Therapies targeting inflammation | ||
Glucocorticoids (dexamethasone, prednisolone, budesonide, etc.) |
Oral solution, inhaled or nebulized preparations Broad spectrum anti-inflammatory Repress the expression of pro-inflammatory cytokines |
Not recommended [44,45] Could be considered where reactive airway disease is strongly suspected (asthma, bronchopulmonary dysplasia, etc.), but no good evidence |
Leukotriene inhibitors (montelukast, etc.) |
Oral solution Inhibit leukotrienes, which are endogenous mediators of inflammation [46] |
Poor evidence, not recommended [47] |
Manual therapies | ||
Chest physiotherapy | Chest percussion, suction Aids in the clearance of secretions Thought to decrease ventilatory effort for infants on the severe end of the disease spectrum |
Not routinely recommended [48] Can be considered when relevant comorbidities are present (neuromuscular conditions, etc.) [49] |